Safety Study of MG1102 in Patients With Solid Tumors
NCT01809912
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumors
Interventions
DRUG:
Recombinant human apolipoprotein(a) Kringle V
Sponsor
Green Cross Corporation
Collaborators
[object Object]